I joined The Scientist as an Assistant Editor in 2023, where I write about discoveries in the life sciences.
Before joining the magazine, I was a a Postdoctoral Research Associate of Neuroscience in Psychiatry at Weill Cornell Medicine. I was also a freelance science writer and I contributed stories to Drug Discovery News and The Scientist.
You can find my recent articles in the Science Communication section below.
Experience
- Postdoctoral Associate in Neuroscience, Weill Cornell Medicine (2018–2023)
Education
-
PhD in Psychology (Behavioral Neuroscience), 2017
Yale University
-
BA in Psychology, 2012
University of Tennessee
Science Communication
Publications
(2023).
Developmental age and fatty acid amide hydrolase genetic variation converge to mediate fear regulation in female mice.
In Developmental Psychobiology.
(2023).
Biological Mechanisms of Anxiety Disorders: Animal and Human Studies.
In Neurobiology of Mental Illness 6th Edition (forthcoming).
(2022).
Experimenters' sex modulates mouse behaviors and neural responses to ketamine via corticotropin releasing factor.
In Nature Neuroscience.
(2022).
The Added Value of Crosstalk Between Developmental Circuit Neuroscience and Clinical Practice to Inform the Treatment of Adolescent Anxiety.
In Biological Psychiatry Global Open Science.
(2021).
Extinction trial spacing across days differentially impacts fear regulation in adult and adolescent male mice.
In Neurobiology of Learning and Memory.
(2021).
An Adolescent Sensitive Period for Threat Responding: Impacts of Stress and Sex.
In Biological Psychiatry.
(2021).
Pre-adolescent stress disrupts adult, but not adolescent, safety learning.
In Behavioural Brain Research.
(2020).
Cell-type specific modulation of NMDA receptors triggers antidepressant actions.
In Molecular Psychiatry.
(2020).
Inhibitory regulation of calcium transients in prefrontal dendritic spines is compromised by a nonsense Shank3 mutation.
In Molecular Psychiatry.
(2020).
GABA interneurons are the cellular trigger for ketamine's rapid antidepressant actions.
In Journal of Clinical Investigation.
(2020).
Ketamine disinhibits dendrites and enhances calcium signals in prefrontal dendritic spines.
In Nature Communications.
(2019).
Role of neuronal VEGF signaling in the prefrontal cortex in the rapid antidepressant effects of ketamine.
In American Journal of Psychiatry.
(2018).
Reshaping the depressed brain: A focus on synaptic health.
In Biological Psychiatry.
(2018).
Predicting barriers to treatment for depression in a U.S. national sample: a cross-sectional, proof-of-concept study.
In Psychiatric Services.
(2018).
Sex-specific molecular changes in depression.
In Biological Psychiatry.
(2018).
Rapid-acting antidepressants: mechanistic insights and future directions.
In Current Behavioral Neuroscience Reports.
(2017).
Cacna1c in the prefrontal cortex regulates depression-related behaviors via REDD1.
In Neuropsychopharmacology.
(2017).
Molecular and cellular mechanisms of rapid-acting antidepressants ketamine and scopolamine.
In Current Neuropharmacology.
(2016).
GABA interneurons mediate the rapid antidepressant-like effects of scopolamine.
In Journal of Clinical Investigation.
(2016).
Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity.
In Drug Discovery Today.
(2015).
A diet enriched with curcumin impairs newly acquired and reactivated fear memories.
In Neuropsychopharmacology.
(2014).
Maintenance of dominance status is necessary for resistance to social defeat stress in Syrian hamsters.
In Behavioural Brain Research.